Skip to content

Paraffin Oil or Coconut Oil in Acute Aluminum Phosphide Poisoning

Gastric Lavage With Paraffin Oil or Coconut Oil in Management of Acute Aluminum Phosphide Poisoning: A Randomized Controlled Clinical Trial.

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04724655
Enrollment
89
Registered
2021-01-26
Start date
2021-01-01
Completion date
2021-09-15
Last updated
2022-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aluminum Phosphide Poisoning

Brief summary

The aim of the present study is to evaluate safety and efficacy of gastric lavage with paraffin oil or gastric lavage with coconut oil in management of acute Aluminum phosphide poisoning.

Detailed description

60 patients will be randomly assigned as control groups, paraffin group, and coconut group in a 1:1:1 ratio (30 patients in each group). Inclusion criteria: * Patients with symptomatic acute aluminum phosphide poisoning * Age is more than 12 years of both gender * Patients presenting within 6 hours post-ingestion of aluminum phosphide (Papade and Vanjari, 2019). The diagnosis is made on the basis of: 1. The suggestive clinical manifestations due to and following shortly after a single exposure to aluminum phosphide. 2. Reliable identification of the compound based on the container brought by patient attendants. 3. Biochemical detection of phosphine gas in gastric aspirate (silver nitrate test). * Group (I): Gastric lavage with saline and sodium bicarbonate 8.4% then aspiration will be done after 3-5 min through nasogastric tube (Control group) * Group (II): Gastric lavage will be initiated with 50 mL of Paraffin oil and 50 mL of sodium bicarbonate solution 8.4%, then aspiration will be done after 3-5 min through nasogastric tube (Paraffin group). * Group (III): Gastric lavage will be initiated with 50 ml coconut oil and 50 ml sodium bicarbonate 8.4 % then aspiration will be done after 3-5 min through nasogastric tube (Coconut group). * All patients will continue to receive the standard supportive treatment according to Tanta University Poison Control Center protocol, which is determined by the attending physician who maintains clinical responsibility for all patients. Conventional standard treatment included using inotropes, fluids and electrolytes resuscitation, intubation, mechanical ventilation and antiarrhythmic agents if indicated.

Interventions

OTHERgastric lavage with paraffin oil and bicarbonate

Gastric lavage will be initiated with 50 mL of Paraffin oil and 50 mL of sodium bicarbonate solution 8.4%, then aspiration will be done after 3-5 min through nasogastric tube

OTHERgastric lavage with coconut oil and bicarbonate

Gastric lavage will be initiated with 50 ml coconut oil and 50 ml sodium bicarbonate 8.4 % then aspiration will be done after 3-5 min through nasogastric tube

DRUGstandard treatment

inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate

OTHERgastric lavage with saline and bicarbonate

Gastric lavage with saline and sodium bicarbonate 8.4% then aspiration will be done after 3-5 min through nasogastric tube

Sponsors

Tanta University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* • Patients with symptomatic acute aluminum phosphide poisoning * Age is more than 12 years of both gender * Patients presenting within 6 hours post-ingestion of aluminum phosphide

Exclusion criteria

* • Patients less than 12 years of age * Pregnant and lactating women. * Patients with ingestion or exposure to other substances in addition to aluminum phosphide. * Patients with other major medical conditions (e.g. cardiovascular disease, diabetes mellitus, renal or hepatic failure).

Design outcomes

Primary

MeasureTime frame
death72 hours

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026